Kanabo Group Plc

-0.15 (-7.5%)
Share Name Share Symbol Market Type Share ISIN Share Description
Kanabo Group Plc LSE:KNB London Ordinary Share GB00BYQCS703 ORD 2.5P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15 -7.5% 1.85 487,483 16:35:16
Bid Price Offer Price High Price Low Price Open Price
1.95 2.05 2.00 1.95 2.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Medical Laboratories 0.07 -4.55 -1.20 - 6.84
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:16 UT 100 1.85 GBX

Kanabo (KNB) Latest News

Kanabo (KNB) Discussions and Chat

Kanabo Forums and Chat

Date Time Title Posts
08/6/202317:29KANABO - Riding the Cannabis Wave 20
07/6/202308:48Kanabo Group Medicinal Cannabis 1,760
25/2/202115:34Kanobo Warrants4
15/2/202113:05Kanabo Group Medicinal Cannabis 2
17/8/200917:18Kinbauri Gold: Alive and Kicking26

Add a New Thread

Kanabo (KNB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-09 15:35:161.851001.85UT
2023-06-09 15:28:391.953086.01O
2023-06-09 15:25:571.9858411.56O
2023-06-09 15:05:161.98500.99O
2023-06-09 15:02:331.9810,000198.00O

Kanabo (KNB) Top Chat Posts

Top Posts
Posted at 08/6/2023 17:29 by chica1
I think this is ripe for a large investment by a whale who has the money to invest in the 'docs on call'division.Its almost impossible to get an in person consult with a GP in a timely manner.
You can't get an online company like that up on running on a shoestring.
Current shareholders might have to take a bath considering the collapse in share price but at least management won't have to come back and tap shareholders every 6 months.
Down the road a well capitalised Kanabo could and probably should be 2 different companies.There is still a stigma about the Cannabis industry even if it is for medical purposes.

That being said it's still a very risky proposition!

Posted at 07/6/2023 07:34 by the crypt
Whichever way you look at it mr moronic sandwich muncher the company share price has gone down massively unless you got in at 2p. You only demonstrate what a massive useless tool that you are. So I will laff at you.
Posted at 16/5/2023 15:04 by smackeraim
announced on 21 February 2022, as part-consideration for the acquisition of The GP Service Limited, Kanabo was due to issue 12,574,931 new Ordinary Shares to MEIF WM Debt LP ("MEIF") on or around 22 August 2023, at an issue price of 12.65p per share.-- Following the successful completion of the GBP2.74 million fundraise by the Company earlier this month, and with the consent of MEIF, the Company believes that it was beneficial for all stakeholders that the issuance date of these consideration shares should be extended to 31 December 2024.-- All other terms of the original February 2022 agreement, aside from this extension date, remain the same, including t he number of shares to be issued, 12,574,931 and the issue price of 12.65p.
Posted at 08/3/2023 08:45 by oakridge
Oakridge8 Mar '23 - 08:41 - 1718 of 1719 Edit
0 0 0
Just thought I'd share a post I've made on the HELD thread, as it may be of interest to KNB'ers.

(KNB have a strategic investment in cultivators HELD, who should be harvesting their maiden crop in a few months time under their massive cultivation license in Greece).

It is likely KNB and HELD will be doing business together in the future, although HELD's initial target market is Germany, where it has already signed two term sheets.

HELD are new to the mkt and currently trade at a barely visible 0.095p (c.£10M mkt cap) and I continue to predict significant upside SHOULD they prove they are operationally competent. First sales anticipated this quarter.


Oakridge8 Mar '23 - 08:35 - 459 of 459 Edit
0 0 0
Correct ash. Should be cropping towards the the end of Q2 all being well. There will be updates at HELD before then however.

An absolute plethora of articles and commentary now appearing on medicinal cannabis, just as I predicted for 2023. New releases and debates on a daily, tv, print, media. Accelerated and bolstered in part thanks to Prince Harry's recent talk of the role of THC and psychedelics in his therapy. Whether you like him or not is irrelevant here of course....what matters is the elevated platform this sector now has and the amount of media focus and discussion around it.

Patient access in the UK will be expanded, in time, imo. We may drag our feet more than other countries...and I'm sure there will be regulatory twists and turns, but the level of prescriptions and usage is now heading in one direction imo. I expect there to be friction within our current conservative administration, but as there already appears to be supply constraints for the limited channels that DO exist, which of course is good for HELD.

Last night there was a very worthwhile phone-in / debate on LBC after midnight. It should be available to listen again. It included doctors, psychologists and interestingly the head of CLEAR (of Cannabis Law Reform). Even the professional commentator who held conservative and cautious perspective towards the prescription of THC conceded that she wouldn't rule out prescribing it in the future and made passing reference to the growing body of evidence in pain control.

Also discussion around the need for clinical trials to gather more data and the complications around this; 'traditional' big pharma drugs often contain only one active molecule, which makes them relatively 'easy' to assess and control in a clinical trial where as cannabis therapeutics can contain several hundred active molecules. That said, the contributors pointed to the growing body of evidence for the likes of pain control and said this bodes well for those who were supportive of increased patient access.

Posted at 15/2/2023 23:26 by oakridge
IMO, HELD most probably have superior cash reserves to KNB at this point in HELD's cash burn rate will, in all likelihood, be somewhat lower than KNB's, both now and as HELD moves through the initial phase 1 cycle this year.

I suggest you look carefully at KNB's interims: at where the money is going, in what kind of quantities and so on. It's not a criticism. I am just pointing to the demands of their business model and just what they are trying to do.

HELD have stated on more than one occasion that the cash from their listing is more than sufficient to get to sales - scheduled as soon as late Q2. It is intended that expansion into Phase 1b and into Phase 2 will be done in line with mkt demand and funded by sales.

As for marketing and distribution, firstly I'm not sure they need to market (much). And they are selling TO distributors (ie they are not distributors themselves).

I think you have a fundamental misunderstanding of the business models of both companies and what each are and, are not, trying to do. Your earlier post trumpeting KNB's business model over HELD's apparent lack of one at all, confirms it.

And once again, I see no reason to pit one company against the other as you are apparently so keen to do. They are trying to enter the market doing different things, albeit with some overlap in places, as I've previously pointed out.

The business models are different. I am not saying one is better than the other but KNB's is certainly more complex to establish as they are aiming for vertical integration and ultimately, control over full supply chain, right down to CE certification and methods and points of delivery, not to mention prescription and opening up patient access.

This is not something that can be done overnight and is potentially infinitely more capital intensive than HELD's phased approach of doing one thing well, over and over.

Without good and ready suppliers of raw material, there is no industry.

There is no primary care, no secondary care, no consultancy firms, no distributors, no vape R&D, no patents, no need for a CE and so on.

Further out I'm sure HELD will want to become involved in genetic banking and contributing in some capacity to clinical trials, but they can be up and running and generating cash well before then.....just as the market currently demands.

Demand for raw material is currently outstripping supply and that demand is rising sharply.

HELD look like they are in with half a chance of contributing meaningfully to that supply and, on info available, being competitive to boot.

Sure enough there are risks to both companies - some of which I'be mentioned in the past. But to pour scorn over one company - particularly for the REASONS you have - and to pit it against the other seems not only pointless but perhaps belies a fundamental misunderstanding of what each respective company is aiming to achieve.

Who knows, KNB might end up being infinitely more successful - I'm open to that scenario - my bets are spread broadly - but it wont, imo, be for your reasoning.


Posted at 14/2/2023 17:56 by oakridge
Currypasty, thank you for that.

FWIW I agree with Tom on this point and posted fairly recently about KNB's cash burn and capital demands at this point in their evolution and made a comparison / contrast to HELD's relatively strong cash position and their respective time frames to meaningful cash generation.

HELD's expenses *should* be relatively few at this stage, and what expenses they do have for the final fit-out of their facilities in Greece should be more than covered by their existing resources: they are funded through to at least first sales and, as the company has stated, they already have term sheets in place good for around a years growth / supply. They are also already in advanced discussions with other European distributors.

KNB, if successful, should be Pan-European. HELD has the same ambition. The difference is, HELD's first revenues will come from the much more ready (and mature) market of Germany.....where as KNB are seeking traction, initially, in the UK.

I don't begrudge KNB's need for capital and it's more of an observation, less a criticism. They are a small company, trying to do a lot. HELD are also a small company, but their business model is more focussed.

As stated, I sliced KNB on the recent climb and effectively have a free carry.....adding to HELD in the meantime when I'm in the mood and whilst the price is just so suppressed.

KNB are owed a decent sum of money, but no saying if or when that will come in and the H1 figures reveal a more than likely need for more money, sooner rather than later.

Their 100% gain in primary care sales is welcome but of course it is coming off an extremely low base. And as you say, no mention of quantities, margins etc

They are both interesting companies. Despite the weak start I do think HELD has significant potential over the next 18 - 24 months. We will know more in Q2 when they should start releasing initial sales figures as well as the scope of further supply contracts in mainland Europe.


Posted at 27/1/2023 10:50 by oakridge
idlejack - you might well be correct re. HELD.

I have now written pretty extensively about that stock and its current predicament....particularly as the fall there has quite a few retail punters up in arms and exasperated by the initial drop in the share price after listing.

As I have tried to explain (perhaps unsuccessfully) to someone only last night: "you are wrong to automatically ASSUME that a falling share price in the meantime is necessarily bad news for those looking to build a position, add or enter the fray".

The weakness at HELD will certainly be uncomfortable for those who are 'all in' and who are in any way unsure about their investment rationale or timelines. But for those who have some form of confidence in the business, or at least believe in the narrative that it will soon be cash generative and meaningfully so, the current weakness and seller in the mkt could be seen as presenting something of an opportunity - especially for those with dry powder. HELD carries risk and uncertainty of course and is in no way a guaranteed winning ticket (at any price).

KNB, due to its earlier arrival (launching into the heady highs of the cannabis sentiment) and relatively slow progress since, is somewhat more advanced along the 'curve of disappointment'.....and that fact, combined with the recent news that they are opening sales channels in respect of medicinal product (not lifestyle), combine to make it look interesting again. As stated, we've been watching it, uninvested, since around the news of their investment into HELD (over a year ago) and only recently began buying the stock.

It goes entirely against human nature to be drawn to weak share prices and poor sentiment and especially because of the woeful year many cannabis stocks have just had specifically, there is likely to be more than a little cynicism washing around in the space.

However I believe 2023 will be the year where some confidence returns to the sector as a whole. As ever, it will be about picking the right ones for the right reasons and at the right prices.


Posted at 26/1/2023 11:20 by wageslave
HELD is tanking today. Perhaps that's impacting on KNB share price.
Posted at 26/1/2023 08:31 by oakridge
I should have added...we are looking at HELD on an 18 - 24 month view and as for KNB we will be interested to assess how they have faired come the end of 2023 and if they manage to achieve any breakthrough sales via the recent products they announced.

Their new routes to market for those same products are of course largely untested...and the current share price here tells you as much. But what is interesting perhaps is the fact that they are on the verge of addressing the medicinal side of the domestic market - which is currently underserved - and where T/O and margins should be infinitely more attractive than the CBD / Lifestyle wing of the company (which is of little interest to us).

News on first sales of those products undertaken with LYPHE via Dispensary Green should hopefully shift perception and mkt sentiment of KNB, in a domestic setting which is slightly lagging behind the overall curve seen in Europe.

The second route to market (via The GP Sevice) is similarly untested, but any penetration here will prove to the market that they have successfully implemented a sales channel that can be rolled out and further expanded.

There are around 17,000 patients receiving medicinal THC in the UK and the findings in the reports (due March) may have implications in regards to the NHS' involvement and indeed the broader acceptance and adoption of practitioners in the private sector.

All in all it is shaping up to be a pivotal year for the space.

The CEO has stated that one of the biggest challenges is obtaining sufficient and consistent quantities of clinical grade material. From that perspective their investment in HELD is interesting.

AIMO etc.

Posted at 26/1/2023 07:50 by oakridge
A good rise off the recent lows here yesterday and supported by the third largest upswing in volume since early 2021.

We have watched KNB from the sidelines for well over a year and since around the time of their strategic investment into Hellenic Dynamics (HELD), which came to market in early December '22 via an RTO and only after a protracted period of regulatory approval.

As peeps here should all know, HELD are cultivators with facilities in located in Greece who are targeting the European market, including the UK, with term sheets already signed for supply into Germany. Initial sales are anticipated in Q2 of this year.

We already hold some shares in HELD but are trying to build a meaningful position there during the current phase of weakness in the share price. This has been aided by a seller in the market together with the likely leave of 'legacy holders' (ie those who were invested in an unrelated company prior to the suspension and RTO), and who are perhaps not aligned with the resulting company and its future.

We have also, finally, become recent and modest buyers of KNB. Aside from KNB's material interest in HELD, the two companies have both some differentiation and overlap. KNB listed into a period of great enthusiasm in respect of the THC space whilst HELD, due to regulatory hurdles and delays surrounding its pioneering status as first cultivator with a main listing, was much later in its arrival.

This delay has been a mixed blessing. Whilst the space cooled considerably in 2022, the future and underlying demand for medicinal cannabis, at this stage at least, appears to have only strengthened.

Many other THC stocks reveal a similar woeful 2022 to that of KNB, trading at a mere fraction of where they were when medicinal cannabis was very much the darling of the moment. The space is still early stage and, in my view, underserved in that it is still very much evolving and defining itself (both on the regulatory front and in terms of adoption and acceptance).

There are now 25 countries in the EU who allow THC dominant medical prescriptions and that number has grown only very recently and continues to grow. In the UK specifically (which sees one of the worst opioid addiction/dependence issues Europe) the market for THC grew by 425% in 2021 alone. The predicted growth rates for Germany over the next five years - a comparatively mature, but still very early stage market - are also impressive.

The space is certainly not without its challenges and obstacles, but whilst many cannabis stocks have had an extremely poor 2022, the actual space itself would seem undiminished. Therefore I think as things open up, and by that I mean through greater adoption and the potential for supportive clinical findings (we are due some in the UK specifically in March) we may begin to see some disconnect emerge between market traction and company valuations and potential.

I will continue to monitor both companies and it will be interesting to see if 2023 is the year which sees a welcome return of favour to this sector as a whole. I think there's a reasonable chance that's on the cards.

AIMO only and NAI. ADYOR etc.

Kanabo share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230610 02:15:46